



MEDICAID / CHIP
PHARMACY PRIOR AUTHORIZATION REQUEST FORM

Zeposia

Phone: 866-841-7659

Fax back to: 866-240-3712

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Member Name:		Prescriber Name:	
Member ID Number:	Fax:	Phone:	
Date of Birth:	Office Contact:		
Member Phone Number:	NPI:	PA PROMISe ID:	
Address:	Address:		
City, State ZIP:	City, State ZIP:		
Line of Business: <input type="checkbox"/> Medicaid <input type="checkbox"/> CHIP	Specialty Pharmacy (if applicable):		
Drug Name:	Strength:		
Quantity:	Refills:		
Directions:			
Diagnosis Code:	Diagnosis:		
<i>Jefferson Health Plans' maximum approval time is 12 months but may be less depending on the criteria..</i>			

Please attach any pertinent medical history including labs and information for this member that may support approval.

Please answer the following questions and sign.

Q1. Is this request for continuation of therapy with Zeposia (ozanimod)?

Yes

No

Q2. Is prescribed Zeposia (ozanimod) for the treatment of a diagnosis that is indicated in the U.S. Food and Drug Administration (FDA)-approved package labeling or a medically accepted indication?

Yes

No

Q3. Is prescribed Zeposia (ozanimod) by or in consultation with an appropriate specialist (i.e., a neurologist for a diagnosis of multiple sclerosis or a gastroenterologist for a diagnosis of ulcerative colitis)?

Yes

No

Q4. Does the patient have a contraindication to Zeposia (ozanimod)?

Yes

No

Q5. Does the patient have a diagnosis of multiple sclerosis?

Yes

No

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document

Zeposia

Phone: 866-841-7659

Fax back to: 866-240-3712

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Member Name:	Prescriber Name:
--------------	------------------

Q6. Does the patient have a history of therapeutic failure of or a contraindication or an intolerance to the preferred Multiple Sclerosis Agents approved for the beneficiary's diagnosis (such as Aubagio, Avonex, Betaseron, Dalfampridine ER Tablet, Dimethyl Fumarate, Gilenya, Glatiramer, Glatopa, Rebif, Rebif Rebidose, Tysabri)?

Yes No

Q7. Does the patient have a current history (within the past 90 days) of being prescribed Zeposia (ozanimod)?

Yes No

Q8. Does the patient have a diagnosis of ulcerative colitis (UC)?

Yes No

Q9. Does the patient have a diagnosis of mild UC that is associated with multiple poor prognostic factors OR moderate to severe UC?

Yes No

Q10. Has the patient 1) Failed to achieve remission with or has a contraindication or an intolerance to an induction course of corticosteroids; 2) Failed to maintain remission with an immunomodulator in accordance with current consensus guidelines (e.g., American College of Gastroenterology, American Gastroenterological Association, European Crohn's and Colitis Organization, etc.) OR has a contraindication or an intolerance to immunomodulators in accordance with current consensus guidelines OR 3) Has achieved remission with Zeposia (ozanimod) AND will be using Zeposia (ozanimod) as maintenance therapy to maintain remission?

Yes No

Q11. Does the patient have a history of therapeutic failure of or a contraindication or an intolerance to the preferred Cytokine and CAM Antagonists approved or medically accepted for treatment of UC or has a current history (within the past 90 days) of being prescribed Zeposia (ozanimod)?

Yes No

Zeposia

Phone: 866-841-7659

Fax back to: 866-240-3712

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Member Name:	Prescriber Name:
--------------	------------------

Q12. Is prescribed a dose that is consistent with the FDA-approved package labeling, nationally recognized compendia, or peer-reviewed medical literature and is age-appropriate according to FDA-approved package labeling, nationally recognized compendia, or peer-reviewed literature?

Yes No

Q13. Is the patient prescribed Zeposia (ozanimod) by or in consultation with an appropriate specialist (i.e., a neurologist for a diagnosis of multiple sclerosis or a gastroenterologist for a diagnosis of ulcerative colitis)?

Yes No

Q14. Is the patient prescribed a dose that is consistent with FDA-approved package labeling, nationally recognized compendia, or peer-reviewed medical literature?

Yes No

Q15. Does the patient have a contraindication to Zeposia (ozanimod)?

Yes No

Q16. Does the patient have a diagnosis of multiple sclerosis?

Yes No

Q17. Does the patient have documented improvement or stabilization of the multiple sclerosis disease course?

Yes No

Q18. Does the patient have a diagnosis of UC?

Yes No

Q19. Has the patient experienced improvement in disease activity and/or level of functioning since starting Zeposia (ozanimod)?

Yes No

Q20. Additional Information:



MEDICAID / CHIP
PHARMACY PRIOR AUTHORIZATION REQUEST FORM

Zeposia

Phone: 866-841-7659

Fax back to: 866-240-3712

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Member Name:	Prescriber Name:

Prescriber Signature

Date

v2026-06